SavedAdd your journal

Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2014 / Cilt: 23 - Sayı: 3

Olmesartana bağlı anjiyoödem, anjiyotensin dönüştürücü enzim inhibisyonu ve kinin peptidazlar tarafından tetiklenir mi? Nadir bir olgu

Is Olmesartan-ınduced angioedema triggered by angiotensin converting enzyme ınhibition and kinin peptides? A rare case

Türkay ÖZCAN
Tolga KÖŞECİ
Kenan TURGUTALP
Ahmet ÇAMSARI
Ahmet KIYKIM
Sezer TURGUTALP ÇİÇEKLİ
Ebru Zeynep ESER
Yavuz GÖZÜKARA
Pages
262–264
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

OM therapy was switched to a calcium channel blocker.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Olmesartan medoxomil (OM) is an angiotensin II receptor blocker (ARB) and it is used for the treatment of hypertension.
📊
Key Findings & Data:While the frequency of angioedema associated with ACEI ranges from 0.1% to 1%, the frequency of ARB-induced angioedema is reported to range from 0.1% to 0.4%.
💡
Conclusion & Impact:OM therapy was switched to a calcium channel blocker.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Olmesartan medoxomil (OM) is an angiotensin II receptor blocker (ARB) and it is used for the treatment of hypertension. Among all ARB drugs, only OM shows an angiotensin converting enzyme inhibitory effect (ACEI). OM may cause angioedema by its ARB effect. It can exhibit this role by the endogenous ACEI effect. While the frequency of angioedema associated with ACEI ranges from 0.1% to 1%, the frequency of ARB-induced angioedema is reported to range from 0.1% to 0.4%. A 38-year-old woman was diagnosed with primary hypertension and 20 mg/day OM was started for the management of hypertension. Following the second day of OM treatment, she was admitted to the emergency department because of a new episode of acute angioedema of the tongue, face and lips. OM induced angioedema was diagnosed. OM therapy was switched to a calcium channel blocker.

Özet

Olmesartan medoxomil (OM), anjiyotensin II reseptör blokeridir (ARB) ve hipertansiyon tedavisi için kullanılır. Tüm ARBler arasında sadece OMnin anjiyotensin dönüştürücü enzim inhibitörü (ADEİ) etkisi vardır. OM, ARB etkisi ile anjiyoödeme neden olur. Bu rolü endojen ADEİ etkisi sayesinde yapar. ADEİ alımından sonra anjiyoödem sıklığı %0,1 ile %1-5 arasında bulunmasına rağmen, ARBlerin neden olduğu anjiyoödemin %0,1 ile %0,4-6 arasında olduğu bildirilmektedir. 38 yaşında kadın hastaya primer hipertansiyon teşhisi kondu. Hipertansiyon tedavisi için 20 mg/gün OM tedavisi planlandı. Hasta, OMnin ikinci gününde dudak, yüz ve dilde meydana gelen akut anjiyoödem nedeniyle hastanemiz acil servise başvurdu. OMnın neden olduğu anjiyoödem teşhisi kondu ve bu nedenle OM tedavisi kalsiyum kanal blokeri ile değiştirildi.

🔖

Cite This Article

ÖZCAN, T., KÖŞECİ, T., TURGUTALP, K., ÇAMSARI, A., KIYKIM, A., ÇİÇEKLİ, S. T., ESER, E. Z., GÖZÜKARA, Y. (2022). Olmesartana bağlı anjiyoödem, anjiyotensin dönüştürücü enzim inhibisyonu ve kinin peptidazlar tarafından tetiklenir mi? Nadir bir olgu. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 23 - Sayı: 3, 262–264. https://ajindex.com/articles/636303

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Zuraw BL, Christiansen SC: Pathophysiology of hereditary angioedema. Am J Rhinol Allergy 2011;25:373-378
  2. Bas M, Hoffmann TK, Kojda G, Bier H: ACE-inhibitor induced angioedema. Laryngorhinootologie 2007;86:804-808
  3. Molinaro G, Cugno M, Perez M, Lepage Y, Gervais N, Agostoni A, Adam A: Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des- arginine(9)-bradykinin. J Pharmacol Exp Ther 2002;303:232-237
  4. Caldeira D, David C, Sampaio C: Tolerability of angiotensin- receptor blockers in patients with intolerance to angiotensin- converting enzyme inhibitors: A systematic review and meta- analysis. Am J Cardiovasc Drugs 2012;12:263-277
  5. Vasquez JL, Jaramillo JC, Fernandez C, Enriquez A, Mielgo R: Severe angioedema associated with olmesartan. Ann Allergy Asthma Immunol 2011;107:285 Bouer IH, Reams GP, Wu Z, Lau-Sieckman A: Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Hum Hypertens 1995;9: 237-243
  6. Campbell DJ, Krum H, Esler MD: Losartan increases bradykinin levels in hypertensive humans. Circulation 2005;111:315-320
  7. Ichikawa S, Takayama Y: Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin- aldosterone system in hypertensive patients. Hypertens Res 2001;24:641-646
  8. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S, Shimamoto K: Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006;29:865-874
  9. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM: Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004;43: 970-976